Literature DB >> 21853229

Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes.

Norihito Doi1, Taiji Sakamoto, Yasushi Sonoda, Miho Yasuda, Koji Yonemoto, Noboru Arimura, Eisuke Uchino, Tatsuro Ishibashi.   

Abstract

BACKGROUND: The present study was performed to compare the effects of pars plana vitrectomy (PPV) and single intravitreaous triamcinolone acetonide (IVTA) on diabetic macular edema (DME) in paired eyes.
METHODS: Prospective comparative study on randomized paired-eyes was carried out at two hospitals. Forty eyes of 20 patients with bilateral DME were included. One randomly-selected eye was treated with PPV (PPV group), and the other eye was treated with IVTA (4 mg, IVTA group). The central macular thickness (CMT) measured by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA) were monitored for 12 months after treatment. Changes from baseline and differences between groups were analyzed using a mixed model.
RESULTS: At 1 and 3 months, CMT decreased significantly in the IVTA group compared to baseline (p < 0.0001 both), but CMT then increased gradually and no significant difference was found at 12 months (p = 0.90). In the PPV group, CMT decreased continuously and reached a significant level at 12 months (p < 0.0001). CMT of the IVTA group was significantly less than that of the PPV group at 1 month (p = 0.009); however, there was no significant difference at 3 months. Conversely, CMT was significantly less in the PPV group than in the IVTA group at 12 months (p = 0.0003). The changes of BCVA paralleled those of CMT, but no significant difference was detected between baseline BCVA and any time point.
CONCLUSIONS: Despite the short-term improvement, DME recurred 6 months after IVTA, while it remained resolved after PPV. Although this study did not reveal a significant change of BCVA with either treatment, PPV resolved DME more effectively than IVTA at 1 year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853229     DOI: 10.1007/s00417-011-1777-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  41 in total

1.  Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid.

Authors:  S D Pendergast; T S Hassan; G A Williams; M S Cox; R R Margherio; P J Ferrone; B R Garretson; M T Trese
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

2.  Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy.

Authors:  Pascale Massin; Graham Duguid; Ali Erginay; Belkacem Haouchine; Alain Gaudric
Journal:  Am J Ophthalmol       Date:  2003-02       Impact factor: 5.258

3.  Pars plana vitrectomy in diabetic macular edema.

Authors:  T Micelli Ferrari; N Cardascia; G Durante; M Vetrugno; L Cardia
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

4.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

5.  Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Robert F Degenring; Bernd A Kamppeter; Ingrid Kreissig; Imren Akkoyun
Journal:  Am J Ophthalmol       Date:  2004-07       Impact factor: 5.258

6.  Goblet cell rebound and airway dysfunction with corticosteroid withdrawal in a mouse model of asthma.

Authors:  David S Southam; Russ Ellis; Jennifer Wattie; William Glass; Mark D Inman
Journal:  Am J Respir Crit Care Med       Date:  2008-10-10       Impact factor: 21.405

Review 7.  Physiology of vitreous surgery.

Authors:  Einar Stefánsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

8.  Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane.

Authors:  J W Harbour; W E Smiddy; H W Flynn; P E Rubsamen
Journal:  Am J Ophthalmol       Date:  1996-04       Impact factor: 5.258

9.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01

10.  One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy.

Authors:  Keita Yamakiri; Taiji Sakamoto; Yoshihiro Noda; Masaaki Nakahara; Nobuchika Ogino; Toshiaki Kubota; Mitsunobu Yokoyama; Mariko Furukawa; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-23       Impact factor: 3.117

View more
  10 in total

Review 1.  Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review.

Authors:  Harrish Nithianandan; Ajay E Kuriyan; Michael J Venincasa; Jayanth Sridhar
Journal:  Clin Ophthalmol       Date:  2020-08-20

2.  Planned foveal detachment technique for the resolution of diffuse diabetic macular edema.

Authors:  Yuki Morizane; Shuhei Kimura; Mio Hosokawa; Yusuke Shiode; Masayuki Hirano; Shinichiro Doi; Mika Hosogi; Atsushi Fujiwara; Yasushi Inoue; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2015-07-30       Impact factor: 2.447

3.  Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study.

Authors:  Ron Adelman; Aaron Parnes; Zofia Michalewska; Barbara Parolini; Claude Boscher; Didier Ducournau
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

4.  Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.

Authors:  Shinri Sato; Hajime Shinoda; Norihiro Nagai; Misa Suzuki; Atsuro Uchida; Toshihide Kurihara; Mamoru Kamoshita; Yohei Tomita; Chigusa Iyama; Sakiko Minami; Kenya Yuki; Kazuo Tsubota; Yoko Ozawa
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

5.  Submacular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema.

Authors:  Samir M El-Baha; Ahmed M Abdel Hadi; Mahmoud A Abouhussein
Journal:  J Ophthalmol       Date:  2019-10-21       Impact factor: 1.909

6.  One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.

Authors:  Qingyun Zhou; Chao Guo; Ailing You; Desai Wang; Wenyan Wang; Xuedong Zhang
Journal:  Mol Vis       Date:  2019-10-21       Impact factor: 2.367

7.  Intravitreal steroids for macular edema in diabetes.

Authors:  Thanitsara Rittiphairoj; Tahreem A Mir; Tianjing Li; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-11-17

8.  The effect of posterior sub-Tenon's capsule triamcinolone acetonide injection to that of pars plana vitrectomy for diabetic macular edema.

Authors:  Sakiko Nonomura; Toshiyuki Oshitari; Miyuki Arai; Eiju Sato; Yoko Takatsuna; Takayuki Baba; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-04-30

9.  Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Nontractional Diabetic Macular Edema.

Authors:  Jan Niklas Ulrich
Journal:  Open Ophthalmol J       Date:  2017-01-31

10.  Vitrectomy with internal limiting membrane peeling versus nonsurgical treatment for diabetic macular edema with massive hard exudates.

Authors:  Hsuan-Chieh Lin; Chung-May Yang; San-Ni Chen; Yi-Ting Hsieh
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.